Home    Back

Fpf1011    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
263Cerebrotendinous xanthomatosis1

263. Cerebrotendinous xanthomatosis    [ 5 clinical trials,   10 drugs,   (DrugBank: 2 drugs),   2 drug target genes,   4 drug target pathways]
Searched query = "Cerebrotendinous xanthomatosis", "27-hydroxylase deficiency", "CYP27 deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 5 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1JPRN-JapicCTI-205157
03/8/202013/02/2020An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3)An open-label study of FPF1011 in patients with cerebrotendinous xanthomatosis (phase 3) Cerebrotendinous xanthomatosisIntervention name : FPF1011
INN of the intervention : Chenodeoxycholic acid
Dosage And administration of the intervention : Dose of chenodeoxycholic acid is 750 mg/day for patients aged 20 or older, and 15 mg/kg/day under ages 20, administered orally in three divided doses a day.
Control intervention name : -
INN of the control intervention : -
Dosage And administration of the control intervention : -		Fujimoto Pharmaceutical CorporationNULLrecruiting0BOTH5Phase 3Japan